Skip to main content
bioMérieux logo

bioMérieux — Investor Relations & Filings

Ticker · BIM ISIN · FR0013280286 LEI · 549300AK8Y0LBIQ4T071 PA Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2022-08-02 Share Issue/Capital Cha…
Country FR France
Listing PA BIM

About bioMérieux

https://www.biomerieux.com/

bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.

Recent filings

Filing Released Lang Actions
Juillet 2022 – Déclaration sur le nombre d’actions composant le capital social et sur le nombre de droits de vote correspondant
Share Issue/Capital Change Classification · 95% confidence The document explicitly states it provides 'Informations mensuelles relatives au nombre total de droits de vote et d'actions' (Monthly information relating to the total number of voting rights and shares) as required by French commercial code (Article L. 233-8 II) and AMF regulations (Article 223-16). This structure, detailing the total number of shares and voting rights as of a specific month-end date (31/07/2022), is characteristic of a regulatory filing concerning share capital and voting rights disclosure, often required monthly in France. While it relates to capital structure, it is not a general financing announcement (CAP) or a share repurchase (POS). It is a specific regulatory disclosure about the current share count and voting power. Given the options, this type of mandatory monthly disclosure about the total number of shares and voting rights is best categorized as a general Regulatory Filing (RNS) or potentially a specific type of Capital/Financing Update (CAP) if a more specific code existed. However, since it is a mandatory, periodic disclosure of share structure details rather than a transaction or fundraising event, RNS (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate general category, although it strongly relates to share structure. Given the highly specific nature of the definitions, and the lack of a dedicated 'Voting Rights/Share Count Disclosure' code, RNS serves as the best fit for a mandatory, non-transactional regulatory update.
2022-08-02 French
bioMérieux receives FDA Clearance for NEPHROCHECK® test on VIDAS®
Regulatory Filings Classification · 95% confidence The document is a press release dated July 28, 2022, announcing that bioMérieux received FDA Clearance for its NEPHROCHECK® test on the VIDAS® platform. It details the medical significance of Acute Kidney Injury (AKI) and the benefits of the new test. This type of announcement, focusing on a specific product/regulatory milestone and providing context, is characteristic of an Earnings Release (ER) or a general press release regarding operational news. Since it is not a full annual report (10-K), a quarterly report (IR), a transcript (CT), or a specific financial filing like a proxy (DEF 14A), the most appropriate classification for a major operational/product announcement that often accompanies or precedes earnings periods is Earnings Release (ER), as it communicates key performance-related news. It is not a Report Publication Announcement (RPA) because it is the substantive news itself, not just an announcement that a report is available.
2022-07-28 English
bioMérieux reçoit l’accréditation de la FDA pour le test NEPHROCHECK® sur VIDAS®
Regulatory Filings Classification · 95% confidence The document is a press release dated July 28, 2022, announcing that bioMérieux received FDA clearance for its NEPHROCHECK® test on the VIDAS® platform. It details the product's utility, quotes executives, and provides company background. This type of announcement, focusing on a specific regulatory milestone or product update that is not a full financial report (like 10-K or IR) or a general regulatory filing (RNS), best fits the category for general corporate news or specific product/regulatory updates that don't align with the other defined categories. Since it is a formal announcement of a significant business/regulatory event (FDA clearance) and not a financial report, earnings release, or management change, it falls under the general 'Regulatory Filings' (RNS) as a catch-all for significant, non-financial, non-meeting related corporate news, or potentially 'Capital/Financing Update' (CAP) if the FDA clearance is viewed as enabling market expansion, but RNS is more appropriate for a product/regulatory clearance announcement that isn't explicitly about financing or M&A. Given the options, RNS serves as the best fit for a press release detailing a specific regulatory achievement.
2022-07-28 French
bioMérieux launches 3P® ENTERPRISE, an innovative solution to address the daily challenges of environmental monitoring in the pharma industry
Environmental & Social Information Classification · 95% confidence The document is a press release dated July 7, 2022, announcing the launch of a new product, '3P® ENTERPRISE,' designed for environmental monitoring in the pharmaceutical industry. It details the features of the new solution (SMART PLATES, CONNECT software, STATION instrument) and its benefits. This type of announcement, focusing on a new product launch and its strategic importance, does not fit the definitions for standard financial reports (10-K, IR, ER, MRQ) or specific corporate actions (DIV, CAP, DIRS). It is a general corporate update or news release. Since there is no specific category for 'Product Launch Announcement,' and it is not a standard regulatory filing like a 10-K or a short announcement of an attached report (RPA/RNS), the most appropriate fallback category is 'Regulatory Filings' (RNS) as a general corporate announcement, although 'Investor Presentation' (IP) or 'Management Reports' (MDA) could be considered if the content were more focused on strategy/results interpretation. Given the nature of a product launch press release, RNS serves as the best general regulatory/corporate announcement category available.
2022-07-07 English
bioMérieux lance 3P® ENTERPRISE, une solution innovante pour relever les défis quotidiens du contrôle de l’environnement dans l’industrie pharmaceutique
Regulatory Filings Classification · 95% confidence The document is a press release dated July 7, 2022, announcing the launch of a new product, '3P® ENTERPRISE,' by bioMérieux, a company in the in vitro diagnostics field. It details the product's features, benefits for the pharmaceutical industry (environmental control), and includes quotes from management and contact information for investors and press. This type of announcement, focusing on a new product launch or significant business development, is typically classified as a general regulatory announcement or press release that doesn't fit the specific financial report categories (like 10-K, ER, IR). Since it is a formal announcement of a business event/product launch and not a specific financial filing, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements not covered elsewhere.
2022-07-07 French
bioMérieux, Boehringer Ingelheim and Evotec launch Aurobac, a joint venture to fight Antimicrobial Resistance
Capital/Financing Update Classification · 95% confidence The document announces the formation of a joint venture named 'Aurobac Therapeutics SAS' by three companies (Boehringer Ingelheim, Evotec, and bioMérieux) to combat Antimicrobial Resistance (AMR). It details the purpose, funding structure (€40 million), and the strategic alignment of the partners. This is a significant corporate action announcement concerning strategic collaboration and financing, but it is not a standard regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a press release detailing a major business development. Since it involves capital contribution and the formation of a new entity, it relates to financing/capital structure changes. However, the primary focus is the strategic partnership and the creation of a new company, which often falls under general corporate news or capital/financing updates. Given the options, 'Capital/Financing Update (CAP)' is the most appropriate fit as it involves a €40 million funding commitment to establish the JV, although 'Regulatory Filings (RNS)' could be a fallback if the nature was purely informational without financial commitment details. Since significant funding is mentioned, CAP is stronger than RNS. It is definitely not a Call Transcript (CT), Earnings Release (ER), or a formal statutory report.
2022-07-06 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.